Contribute to the fight against COVID-19
The challenge
COVID-19 is an unprecedented public health challenge – but we can beat it by working together. Researchers around the world are working on novel therapeutics and vaccines to treat and prevent COVID-19. However, their work is often hindered:
- Many laboratories, scientific suppliers, and researchers themselves are in lockdown, or have to adhere to social distancing, preventing them from conducting their life-saving research.
- Often there is lack of access to specialised equipment and expertise, making it more difficult to do meaningful experiments.
- Timelines are immensely tight, as the global efforts to halting the spread of SARS-CoV-2 and treating those suffering from COVID-19 must not get delayed.
JAK Inhibitors Deep Profiling Demonstration
The Arctoris platform enables accelerated COVID-19 research globally
We offer our robotic platform, state-of-the-art equipment, and full support from our experienced team to assist any researcher in accelerating their COVID-19 research from bench to bedside. To that end, Arctoris has established and validated a set of key assays, including biochemical assays against the SARS-CoV-2 main protease (Mpro), papain-like protease (PLpro), Spike:ACE2 and several others. Arctoris enables researchers to conduct precise therapeutics and vaccine research at the click of a button – fully remotely, even when you and your lab are in lockdown, enabling a broad range of assays to support your work on COVID-19.
Biochemical Profiling
Human & SARS-CoV-2 targets of relevance to COVID-19-
Human targets: JAK1, JAK2, JAK3, TYK2
-
SARS-CoV-2 targets: Mpro, PLpro, Spike/ACE2 PPI
-
RNA dependent RNA polymerase
-
Mechanistic and kinetic insights
Molecular Assays
SARS-CoV-2 pathogen detection (research purposes only)-
qPCR/digital PCR: SARS CoV-2 nucleic acid detection
-
Gene expression panels >550 genes
-
Elucidate inflammatory & signalling pathways
-
Monitor expression levels of markers
Cellular Assays
Immunoassay solutions for viral research-
Cytokine detection: Lumit™/ELISA
-
Access to primary cells
-
Multiplex cytotoxicity assays
-
Gain insights into immune responses
JAK Inhibitors Deep Profiling Demonstration
Following Novartis’ announcement of a Phase III clinical trial to repurpose JAK kinase inhibitor Ruxolitinib/Jakafi to treat severe COVID-19, Arctoris has deployed its unique platform to generate comprehensive mechanistic pharmacology for both marketed and research inhibitors against this family of kinases to understand new therapeutic opportunities.
- Onboarding: 4 target-based assays (JAK1, JAK2, JAK3, and TYK2)
- Deep mechanistic profiling: 24 small molecule inhibitors (8 marketed, 16 research) against the panel of kinases; fully automated in <10 hours
- Analysis: 45,848 IC50s and over 1 million data points to give a range of full potency, kinetic and mechanistic insights of the inhibitors
- Timeline: less than 100 hours in total including 4 new assays developed, optimised & fully automated, and comprehensive datasets generated
Comprehensive biochemical profiling using contact-free picolitre digital dispensing technology & true independent experimentation
Comparative potency, selectivity and kinetic studies against a panel of kinase targets
READY TO GET STARTED?
To find out how to accelerate your project timelines and generate higher quality data, reach out to us today.
